Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease

International Journal of Clinical Practice

Volumn 65, Issue 12, 2011, Pages 1289-1294

  Kalinderi, K ^a   Fidani, L ^a   Katsarou, Z ^b   Bostantjopoulou, S ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ISTRADEFYLLINE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PRAMIPEXOLE; TOLCAPONE;

COMT GENE; DOPAMINE TRANSPORTER GENE; DRD1 GENE; DRD2 GENE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DYSKINESIA; GABAERGIC SYSTEM; GENE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LOW DRUG DOSE; MAO A GENE; MAO B GENE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM;

ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; FORECASTING; HUMANS; MONOAMINE OXIDASE; PARKINSON DISEASE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE;

EID: 81755178727     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02793.x     Document Type: Review

References (56)

1. de Lau L, Breteler M,. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-35. (Pubitemid 44262284)
2. Chaudhuri R, Schapira A,. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-74.
3. Lesage S, Brice A,. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18 (R1): R48-59.
4. Singh N, Pillay V, Choonara YE,. Advances in the treatment of Parkinson's disease. Prog Neurobiol 2007; 81: 29-44. Review. (Pubitemid 46282270)
5. Olanow C, Stern M, Sethi K,. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009; 72 (Suppl 4): S1-136.
6. Sethi K,. l-Dopa unresponsive symptoms in Parkinson disease. Mov Disord 2008; 23 (Suppl 3): S521-33.
7. Fox S, Lang A,. l-Dopa-related motor complications-phenomenology. Mov Disord 2008; 23 (Suppl 3): S509-14.
8. Factor S,. Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics 2008; 5: 164-80. (Pubitemid 351446205)
9. Bonuccelli U, Del Dotto P, Rascol O,. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism Relat Disord 2009; 15: S44-53.
10. Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silva P,. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev 2007; 13: 352-79.Review. (Pubitemid 47481088)
11. Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR,. Tolcapone and fulminant hepatitis. Lancet 1998; 352: 958. (Pubitemid 28427283)
12. Hauser RA, Lew MF, Hurtig HI, et al., Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009; 24: 564-73.
13. Olanow CW, Rascol O, Hauser R, et al., A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-78.
14. Ahlskog JE, Uitti RJ,. Rasagiline, Parkinson neuroprotection, and delayed-start trials. Still no satisfaction? Neurology 2010; 74: 1143-8.
15. Rascol O, Fitzer-Attas CJ, Hauser R, et al., A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011; 10: 415-23.
16. O'Shaughnessy KM,. HapMap, pharmacogenomics,and the goal of personalized prescribing. Br J Clin Pharmacol 2006; 61: 783-6. Review. (Pubitemid 43794811)
17. Salisbury BA, Pungliya M, Choi JY, Jiang R, Sun XJ, Stephens JC,. SNP and haplotype variation in the human genome. Mutat Res 2003; 526: 53-61. (Pubitemid 36507212)
18. BiaÅecka M, Droździk M, KÅodowska-Duda G, et al., The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand 2004; 110: 260-6.
19. Liu YZ, Tang BS, Yan XX, et al., Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients. Eur J Clin Pharmacol 2009; 65: 679-83.
20. Lotta T, Vidgren J, Tilgmann C, et al., Kinetics of human soluble and membrane-bound catechol-O-methyltransferase;a revised mechanism and description of the termolabile variant of the enzyme. Biochemistry 1995; 34: 4202-10.
21. Lee MS, Lyoo ChH, Ulmanen I, Syvanen AC, Rinne JO,. Genotypes of catechol-O-methyltransferase and response to l-Dopa treatment in patients with Parkinson's disease. Neurosci Lett 2001; 298: 131-4. (Pubitemid 32040894)
22. Watanabe M, Harada S, Nakamura T, et al., Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology 2003; 48: 190-3. (Pubitemid 37548226)
23. Contin M, Martinelli P, Mochi M, Riva R, Albani F, Baruzzi A,. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic- pharmacodynamic pattern in patients with Parkinson's disease. Mov Disord 2005; 20: 734-9. (Pubitemid 41051785)
24. Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M,. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics 2008; 18: 815-21.
25. Rivera-Calimlim L, Reilly DK,. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasian; difference in l-Dopa tolerance. Clin Pharmacol Ther 1984; 35: 804-9. (Pubitemid 14077487)
26. Routtinen HM,. COMT genotypes and response to l-Dopa in Parkinson's disease; influence of COMT inhibition with entacapone. Mov Disord 1998; 13: 120.
27. Corvol JC, Bonnet C, Charbonnier-Beaupel F, et al., The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann Neurol 2011; 69: 111-8.
28. Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RM, Brant R, Campbell NR,. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol 2000; 23: 143-8. (Pubitemid 30395375)
29. Tan EK, Cheah SY, Fook-Chong S, et al., Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2005; 137: 1-4. (Pubitemid 41076604)
30. Frauscher B, Hogl B, Maret S, et al., Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease; a pilot study. Sleep 2004; 27: 733-6. (Pubitemid 38823371)
31. Hsu YP, Powell JF, Sims KB, Breakefield XO,. Molecular genetics of monoamine oxidases. J Neurochem 1989; 53: 12-8.
32. Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin E,. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet 2002; 110: 1-7. (Pubitemid 36067410)
33. Arbouw ME, van Vugt JP, Egberts TC, Guchelaar HJ,. Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. Pharmacogenomics 2007; 8: 159-76. Review.
34. Wang J, Liu ZL, Chen B,. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 2001; 56: 1757-9. (Pubitemid 32574582)
35. Paus S, Grünewald A, Klein C, et al., The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease. Mov Disord 2008; 23: 599-602.
36. Neville MJ, Johnstone EC, Walton RT,. Identification and characterization of ANKK1; a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004; 23: 540-5. (Pubitemid 38720604)
37. Rissling I, Geller F, Bandmann O, et al., Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks". Mov Disord 2004; 19: 1279-84. (Pubitemid 39534543)
38. Jonsson EG, Nothen MM, Grunhage F, et al., Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4: 290-6. (Pubitemid 29292183)
39. Makoff AJ, Graham JM, Arranz MJ, et al., Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics 2000; 10: 43-8. (Pubitemid 30142812)
40. Zappia M, Annesi G, Nicoletti G, et al., Sex differences in clinical and genetic determinants of l-Dopa peak-dose dyskinesias in Parkinson disease; an exploratory study. Arch Neurol 2005; 62: 601-5. (Pubitemid 40489893)
41. Strong JA, Dalvi A, Revilla FJ, et al., Genotype and smoking history affect risk of l-Dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2006; 21: 654-9. (Pubitemid 43792746)
42. Kaiser R, Hofer A, Grapengiesser A, et al., l-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003; 60: 1750-5. (Pubitemid 36737068)
43. Paus S, Gadow F, Knapp M, Klein C, Klockgether T, Wüllner U,. Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. Mov Disord 2009; 24: 1080-4.
44. Paus S, Seeger G, Brecht HM, et al., Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease. Mov Disord 2004; 19: 705-7. (Pubitemid 39173028)
45. Wang J, Liu ZL, Chen B,. Dopamine D5 receptor gene polymorphism and the risk of l-Dopa-induced motor fluctuations in patients with Parkinson's disease. Neurosci Lett 2001; 308: 21-4. (Pubitemid 32607671)
46. Hyman C, Hofer M, Barde YA, et al., BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350: 230-2. (Pubitemid 21912205)
47. Spina MB, Hyman C, Squinto S, Lindsay RM,. Brain-derived neurotrophic factor protects dopaminergic cells from 6-hydroxydopamine toxicity. Ann N Y Acad Sci 1992; 648: 348-50.
48. Egan MF, Kojima M, Callicott JH, et al., The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-69. (Pubitemid 36144114)
49. Foltynie T, Cheeran B, Williams-Gray C, et al., BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009; 80: 141-4.
50. Guerini F, Beghi E, Riboldazzi G, et al., BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. Eur J Neurol 2009; 16: 1240-5.
51. Foltynie T, Lewis S, Goldberg T, et al., The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol 2005; 252: 833-8. (Pubitemid 40984861)
52. Gao L, DÄaz-Corrales FJ, Carrillo F, et al., Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson's disease. Acta Neurol Scand 2010; 122: 41-5.
53. Karakasis C, Kalinderi K, Katsarou Z, Fidani L, Bostantjopoulou S,. Brain-Derived Neurotrophic Factor (BDNF) Val66Met polymorphism in Greek patients with Parkinson's disease. J Clin Neurosci; doi: 10.1016/j.jocn.2011.03.015.
54. Cunha RA,. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system; different roles, different sources and different receptors. Neurochem Int 2001; 38: 107-25. (Pubitemid 32014381)
55. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF,. Adenosine, adenosine A2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 406-13. Review.
56. Hauser RA, Hubble JP, Truong DD, and Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003; 61: 297-303. (Pubitemid 36975955)